178 related articles for article (PubMed ID: 37353349)
21. [Clinical analysis in a cohort of 102 patients with myelodysplastic syndrome characterized by erythroid hyperplasia].
Yu Y; Sun AN; Chen SN; Wang QR; Zhang TT; Wu DP
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):29-33. PubMed ID: 28056320
[No Abstract] [Full Text] [Related]
22. Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.
Xiong H; Yang XY; Han J; Wang Q; Zou ZL
Braz J Med Biol Res; 2015 Mar; 48(3):207-13. PubMed ID: 25608238
[TBL] [Abstract][Full Text] [Related]
23. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
24. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review.
Ganguly BB; Dolai TK; De R; Kadam NN
J Cancer Res Ther; 2016; 12(3):1203-1206. PubMed ID: 28054536
[TBL] [Abstract][Full Text] [Related]
26. [Somatic Mutations of Acquired Aplastic Anemia].
Zhang ML; Chen WS; Han B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):491-496. PubMed ID: 35791949
[TBL] [Abstract][Full Text] [Related]
27. Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome.
Wen JQ; Feng HL; Wang XQ; Pang JP
World J Pediatr; 2008 Feb; 4(1):36-40. PubMed ID: 18402250
[TBL] [Abstract][Full Text] [Related]
28. Childhood myelodysplastic syndrome.
Chatterjee T; Choudhry VP
Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
[TBL] [Abstract][Full Text] [Related]
29. The current perspective of low-grade myelodysplastic syndrome in children.
Hasegawa D
Int J Hematol; 2016 Apr; 103(4):360-4. PubMed ID: 26939774
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathogenesis of MDS.
Look AT
Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
32. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
33. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
34. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
35. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
36. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
[TBL] [Abstract][Full Text] [Related]
37. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
38. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
39. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
[TBL] [Abstract][Full Text] [Related]
40. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).
Koh Y; Lee HR; Song EY; Kim HK; Kim I; Park S; Park MH; Kim BK; Yoon SS; Lee DS
Leuk Res; 2010 Oct; 34(10):1344-50. PubMed ID: 20427085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
